Overview

• The nationwide Danish cohort study linked vaccination and health outcome records for more than 1.2 million children born between 1997 and 2018 using unique personal ID numbers
• Researchers found that aluminum doses from nonlive vaccines in the first two years of life were not associated with increased rates of any of 50 assessed chronic conditions spanning autoimmune, allergic and neurodevelopmental categories
• Adjusted hazard ratios per 1 mg increase in aluminum dose were close to 1 for autoimmune (HR 0.98) and allergic disorders (HR 0.99) and indicated a slight risk decrease for neurodevelopmental disorders (HR 0.93)
• The study acknowledges its observational nature and notes that very small effects, especially for rare outcomes, cannot be completely ruled out without individual medical record review
• Lead investigators plan to continue following the cohort into older ages to assess cognitive outcomes and bolster the evidence base during ongoing vaccine adjuvant policy discussions